An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-naïve EGFR-mutant Locally Advanced or Metastatic NSCLC

Status: Closed to Accrual

Learn more:

• https://clinicaltrials.gov/study/NCT03909334
• See news release

Manuscripts/Articles:

• Xiuning Le, Jyoti D. Patel, Elaine Shum, Christina Baik, Rachel E. Sanborn, Catherine A. Shu, Chul Kim, Mary Jo Fidler, Richard Hall, Yasir Y. Elamin, Janet Tu, George Blumenschein, Jianjun Zhang, Don Gibbons, Carl Gay, Nisha A. Mohindra, Young Chae, Yanis Boumber, Joshua Sabari, Rafael Santana-Davila, Shane Rogosin, Benjamin Herzberg, Ben Creelan, Bruna Pellini, Tawee Tanvetyanon, Simon Heeke, Mike Hernandez, Jhanelle E. Gray, Andreas Saltos, John V. Heymach.A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor–Naïve EGFR-Mutant Metastatic Non–Small Cell Lung Cancer (RAMOSE trial): Hoosier Cancer Research Network LUN18-335. DOI: 10.1200/JCO.24.00533 Journal of Clinical Oncology. 2024 October. See Abstract. 

Abstracts/Posters/Presentations:

• X Le, J Patel, E Shum, J Sabari, C Baik, R Sanborn, K Shu, C Kim, M Jo Fidler, R Hall, N Hanna, J Gray, JV Heymach, A Saltos. LBA71 – A multi-centre open-label randomized phase II study of osimertinib with and without ramucirumab in TKI-naïve EGFR-mutant metastatic NSCLC (RAMOSE trial interim analysis)(HCRN-LUN18-335). Presented as a mini oral session at the 2023 EMSO Congress. See abstract. 
• A. Saltos, C. Baik, R.E. Sanborn, E. Shum, C. Kim, R. Hall, M.J. Fidler, C.A. Shu, G. Otterson, J. Patel, K.K. Wong, N. Hanna, J. Gray, J. Heymach, X. Le. RAMOSE: An Open-Label Randomized Phase II Study of Osimertinib with or without Ramucirumab in TKI-naïve EGFR-mutant Metastatic NSCLC. Presented at the IASLC 2020 World Conference on Lung Cancer. See abstract.

Study Contact: studies@hoosiercancer.org; (317) 921-2050.